Inhaled pan-phosphodiesterase inhibitors ameliorate ovalbumin-induced airway inflammation and remodeling in murine model of allergic asthma

Wójcik-Pszczoła, Katarzyna; Pociecha, Krzysztof; Chłoń-Rzepa, Grażyna; Zadrożna, Monika; Nowak, Barbara; Plutecka, Hanna; Koczurkiewicz-Adamczyk, Paulina; Przejczowska-Pomierny, Katarzyna; Pękala, Elżbieta; Gosens, Reinoud; Wyska, Elżbieta

doi:10.1016/j.intimp.2023.110264

Cited by 3 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although asthma was previously considered a reversible air ow limitation, long-term stimulation of chronic airway in ammation may lead to irreversible airway structural remodeling in some patients [19]. Airway remodeling is characterized by smooth muscle hypertrophy or hyperplasia, mucus gland hyperplasia, vascular proliferation, deposition of extracellular matrix in the submucosal and adventitial layers, as well as collagen and protein deposition beneath the epithelium [20][21][22], collectively leading to increased airway hyperresponsiveness and air ow obstruction [23].…”

Section: Discussionmentioning

confidence: 99%

Utilizing chest CT to assess the impact of omalizumab treatment on airway remodeling in refractory asthma

Shi,

Chen,

Lei

et al. 2023

Preprint

View full text Add to dashboard Cite

Background To evaluate the benefits of omalizumab treatment in patients through real-world clinical follow-up data and assess the impact of omalizumab treatment on airway remodeling using chest CT. Methods This is a single-center prospective cohort study conducted in the Department of Respiratory and Critical Care Medicine of our hospital from May 2021 to December 2022, focusing on refractory asthma patients who received omalizumab treatment during this period. A comparison was made between the pre-treatment and post-treatment laboratory indicators, pulmonary function parameters, airway parameters, and mucous plug scores obtained from chest CT. Results This study included a total of 61 patients with refractory asthma treated with omalizumab. The study found that: ①regardless of whether the treatment lasted for a full four months or not, it significantly improved patient asthma control scores and reduced hospitalization costs and length of stay (p < 0.05). ②After four months of treatment, patients showed a decrease in FENO levels and central airway resistance (Rc) (p < 0.05) as measured by airway resistance examination. Pulmonary ventilation function examination revealed significant improvements (p < 0.05) in MEF75, MEF50, MEF75/25, PEF, and FEV1/FVC. ③After four months of omalizumab treatment, the ratio of wall thickness and outer radius (T/D) and wall area percentage (WA%) of the bronchial wall decreased significantly (p < 0.05). ④After medication, the expression of airway mucous plugs decreased. The mucous plug score was negatively correlated with several indicators of large and small airway function. Conclusions Omalizumab treatment can remodel the airways in refractory asthma patients, reducing airway wall thickness, decreasing the percentage of airway wall area, and reducing the expression of airway mucous plugs, thereby improving airflow limitation. Utilizing chest CT provides a novel and intuitive assessment of the efficacy of omalizumab treatment, offering a new perspective for the analysis of omalizumab treatment efficacy. Trial registration: This study was registered in Chinese Clinical Trial Registry, the number is ChiCTR2100046343.

show abstract

Section: Discussionmentioning

confidence: 99%

Utilizing chest CT to assess the impact of omalizumab treatment on airway remodeling in refractory asthma

Shi,

Chen,

Lei

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

The Role of Transforming Growth Factor-β (TGF-β) in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Kraik,

Tota,

Laska

et al. 2024

Cells

View full text Add to dashboard Cite

Asthma and chronic obstructive pulmonary disease (COPD) represent chronic inflammatory respiratory disorders that, despite having distinct pathophysiological underpinnings, both feature airflow obstruction and respiratory symptoms. A critical component in the pathogenesis of each condition is the transforming growth factor-β (TGF-β), a multifunctional cytokine that exerts varying influences across these diseases. In asthma, TGF-β is significantly involved in airway remodeling, a key aspect marked by subepithelial fibrosis, hypertrophy of the smooth muscle, enhanced mucus production, and suppression of emphysema development. The cytokine facilitates collagen deposition and the proliferation of fibroblasts, which are crucial in the structural modifications within the airways. In contrast, the role of TGF-β in COPD is more ambiguous. It initially acts as a protective agent, fostering tissue repair and curbing inflammation. However, prolonged exposure to environmental factors such as cigarette smoke causes TGF-β signaling malfunction. Such dysregulation leads to abnormal tissue remodeling, marked by excessive collagen deposition, enlargement of airspaces, and, thus, accelerated development of emphysema. Additionally, TGF-β facilitates the epithelial-to-mesenchymal transition (EMT), a process contributing to the phenotypic alterations observed in COPD. A thorough comprehension of the multifaceted role of TGF-β in asthma and COPD is imperative for elaborating precise therapeutic interventions. We review several promising approaches that alter TGF-β signaling. Nevertheless, additional studies are essential to delineate further the specific mechanisms of TGF-β dysregulation and its potential therapeutic impacts in these chronic respiratory diseases.

show abstract

Inhalational Drug Devices: Revisiting the Linchpin of Asthma Management

Saxena,

Murugesan,

Evbayiro

et al. 2024

JPM

View full text Add to dashboard Cite

Asthma remains a prevalent condition among all age groups globally. First-line treatment requires the delivery of medications into the distal respiratory tract via inhalers. Using appropriate inhaler techniques is a significant challenge in achieving disease control. A variety of inhalers are available for treating asthma, and selecting the appropriate inhaler type for any given patient is crucial to achieving and maintaining symptomatic control. This review will discuss the anatomy and physiology behind drug delivery via inhalers, the types of inhalers currently available for use, nebulizers, and future directions in the delivery of inhaled medications for asthma.

show abstract

Inhaled pan-phosphodiesterase inhibitors ameliorate ovalbumin-induced airway inflammation and remodeling in murine model of allergic asthma

Cited by 3 publications

References 56 publications

Utilizing chest CT to assess the impact of omalizumab treatment on airway remodeling in refractory asthma

Utilizing chest CT to assess the impact of omalizumab treatment on airway remodeling in refractory asthma

The Role of Transforming Growth Factor-β (TGF-β) in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Inhalational Drug Devices: Revisiting the Linchpin of Asthma Management

Contact Info

Product

Resources

About